Lilly's bamlanivimab with etesevimab authorized as the first and only neutralizing antibody therapy for emergency use in COVID-19 patients under the age of 12

Expanded EUA includes both treatment of patients with COVID-19 and post-exposure prophylaxis (PEP) in high-risk pediatric and infant patients INDIANAPOLIS , Dec. 3, 2021 /PRNewswire/ -- The U.S.   Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) for bamlanivimab